StockDriftsStockDriftsHLB Pharmaceuticals (047920) has 0 disclosed insider purchases and 1 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩262M ($182K) in reported transaction value. The earliest filing StockDrifts holds for HLB Pharmaceuticals is dated 2024-03-11; the most recent is 2025-05-09. Across these filings the average return since disclosure is +39.01%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-08-26 | SELL | Market Sell | 임철안 Lim Cheol-an | Managing Director | -3.3K | ₩7,250 | +0.3% | ₩24M ($17K) |
| 2026-08-25 | SELL | 장외매도 | 진양곤 Jinyanggon | moving | -129.0K | ₩7,630 | +5.2% | ₩985M ($684K) |
| 2026-08-25 | SELL | 장외매도 | HLB생명과학 HLB Life Science | - | -869.3K | ₩7,630 | +5.2% | ₩6.6B ($4.6M) |
| 2026-08-25 | SELL | 장외매도 | 박재형 Jaehyung Park | CEO | -92.7K | ₩7,630 | +5.2% | ₩707M ($491K) |
| 2026-08-19 | BUY | 기타 | 진양곤 Jinyanggon | moving | 258.1K | - | - | - |
| 2026-08-19 | BUY | 기타 | 임철안 Lim Cheol-an | Managing Director | 3.3K | - | - | - |
| 2026-08-19 | BUY | 기타 | HLB생명과학 HLB Life Science | - | 1.7M | - | - | - |
| 2026-08-19 | BUY | 기타 | 박재형 Jaehyung Park | CEO | 185.3K | - | - | - |
| 2025-05-09 | BUY | 유상신주취득 | HLB생명과학 HLB Life Science | - | 976.4K | ₩20,850 | -23.4% | ₩20.4B ($14.1M) |
| 2024-03-11 | SELL | Market Sell | 임철안 Lim Cheol-an | moving | -10.0K | ₩26,200 | +39.0% | ₩262M ($182K) |
Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.